AR125974A1 - Un sistema de triple co-cultivo para la detección de fármacos de células cancerosas derivadas de pacientes y métodos de uso de - Google Patents

Un sistema de triple co-cultivo para la detección de fármacos de células cancerosas derivadas de pacientes y métodos de uso de

Info

Publication number
AR125974A1
AR125974A1 ARP220101388A ARP220101388A AR125974A1 AR 125974 A1 AR125974 A1 AR 125974A1 AR P220101388 A ARP220101388 A AR P220101388A AR P220101388 A ARP220101388 A AR P220101388A AR 125974 A1 AR125974 A1 AR 125974A1
Authority
AR
Argentina
Prior art keywords
cell
triple
derived
patient
culture
Prior art date
Application number
ARP220101388A
Other languages
English (en)
Inventor
Ramiro Gastn Soria
De Los Ros Mara Candelaria Gatti Gerardo Alberto Zaki Tarek Ali Llorens
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Oncoprecision Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Oncoprecision Corp filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR125974A1 publication Critical patent/AR125974A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona un cocultivo triple de una célula cancerosa derivada de un paciente (PDC), una célula no derivada de un tumor que apoya el crecimiento del PDC y, opcionalmente, puede servir como control interno de celda normal (una célula “Control Tox” o “TC”) y una célula derivada de un tumor distinta de una derivada del paciente y que exhiba sensibilidad a al menos un fármaco anticanceroso o combinación de fármacos (una celda de “Control del sistema”). La presente divulgación proporciona además métodos para usar dichos sistemas de cocultivo triple en, por ejemplo, medicina personalizada ex vivo, descubrimiento de fármacos, creación de fármacos y validación preclínica de candidatos para ensayos clínicos. Reivindicación 1: Una composición de cocultivo triple caracterizada porque comprende: una primera célula, donde la primera célula es una célula cancerosa derivada del paciente; una segunda célula, donde la segunda célula es una célula no derivada de un tumor que soporta el crecimiento y/o la viabilidad de la primera célula; y una tercera célula, donde la tercera célula es una célula derivada de un tumor que no procede del paciente y que presenta sensibilidad a al menos un fármaco anticanceroso o una combinación de fármacos. Reivindicación 26: Un método para detectar una respuesta de una célula cancerosa derivada de un paciente a una terapia contra el cáncer caracterizada porque comprende: cultivar el cocultivo triple según una cualquiera de las reivindicaciones 1 a 25 en presencia de un agente de prueba, donde el agente de prueba es una terapia contra el cáncer o una terapia contra el cáncer candidata; y detectar la respuesta al agente de prueba de la primera célula, la segunda célula y la tercera célula. Reivindicación 37: Un método para analizar un conjunto de agentes de prueba caracterizada porque comprende: cultivar un conjunto de cocultivos triples, donde cada cocultivo triple del conjunto comprende el cocultivo triple según una cualquiera de las reivindicaciones 1 a 25 y donde cada cocultivo triple del conjunto comprende la misma célula cancerosa derivada del paciente y la misma segunda y tercera célula; administrar a cada cocultivo triple del conjunto un agente de prueba diferente del conjunto de agentes de prueba o una concentración diferente del mismo agente de prueba; y detectar una respuesta a los agentes de prueba de la primera célula, la segunda célula y la tercera célula en cada cocultivo triple.
ARP220101388A 2021-05-27 2022-05-26 Un sistema de triple co-cultivo para la detección de fármacos de células cancerosas derivadas de pacientes y métodos de uso de AR125974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163194051P 2021-05-27 2021-05-27

Publications (1)

Publication Number Publication Date
AR125974A1 true AR125974A1 (es) 2023-08-30

Family

ID=84229223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101388A AR125974A1 (es) 2021-05-27 2022-05-26 Un sistema de triple co-cultivo para la detección de fármacos de células cancerosas derivadas de pacientes y métodos de uso de

Country Status (3)

Country Link
EP (1) EP4319882A1 (es)
AR (1) AR125974A1 (es)
WO (1) WO2022251475A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10295530B2 (en) * 2012-08-28 2019-05-21 The Brigham And Women's Hospital, Inc. Functional assay for cancer recurrence and malignant potential
JP2017516499A (ja) * 2014-05-19 2017-06-22 ユニバーシティ・オブ・サウス・フロリダ 多細胞チューモロイドの形成およびその使用

Also Published As

Publication number Publication date
WO2022251475A1 (en) 2022-12-01
EP4319882A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
Ayuso et al. Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations
Hirth et al. CXCL10 and CCL21 promote migration of pancreatic cancer cells toward sensory neurons and neural remodeling in tumors in mice, associated with pain in patients
Seker-Polat et al. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives
Sinha et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling
Seo et al. Triculture model of in vitro BBB and its application to study BBB‐associated chemosensitivity and drug delivery in glioblastoma
Hakim et al. Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling
Faris et al. Nicotinic acid adenine dinucleotide phosphate (NAADP) induces intracellular Ca2+ release through the two-pore channel TPC1 in metastatic colorectal cancer cells
Cerniglia et al. The PI3K/Akt pathway regulates oxygen metabolism via pyruvate dehydrogenase (PDH)-E1α phosphorylation
Holton et al. Microfluidic biopsy trapping device for the real-time monitoring of tumor microenvironment
Scaringi et al. NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1α
Chikano et al. Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway
Yan et al. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity
Riehl et al. Fluid-flow-induced mesenchymal stem cell migration: role of focal adhesion kinase and RhoA kinase sensors
Valtorta et al. Molecular and cellular complexity of glioma. Focus on tumour microenvironment and the use of molecular and imaging biomarkers to overcome treatment resistance
Garg et al. Electromagnetic fields alter the motility of metastatic breast cancer cells
Meng et al. Pinin promotes tumor progression via activating CREB through PI3K/AKT and ERK/MAPK pathway in prostate cancer
Sulzmaier et al. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics
Komen et al. Viability analysis and apoptosis induction of breast cancer cells in a microfluidic device: effect of cytostatic drugs
CN107586781A (zh) 肝癌标志物lncRNA ENST00000620463.1及其应用
Ueno et al. Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system
Cao et al. Evaluation of the skin sensitization potential of chemicals in THP-1/keratinocyte co-cultures
Ren et al. Metformin inactivates the cGAS-STING pathway through autophagy and suppresses senescence in nucleus pulposus cells
Wang et al. The third‐generation retinoid adapalene triggered DNA damage to induce S‐phase arrest in HaCat cells
Chen et al. Targeting cholesterol transport in circulating melanoma cells to inhibit metastasis
Mazumder et al. Integrating pharmacogenomics data-driven computational drug prediction with single-cell RNAseq to demonstrate the efficacy of a NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer